Download PDF
Hamostaseologie 2009; 29(01): 7-16
DOI: 10.1055/s-0037-1616932
Original article
Schattauer GmbH

Blood coagulation dynamics in haemostasis

K. G. Mann
1   University of Vermont, Burlington, VT USA
,
T. Orfeo
1   University of Vermont, Burlington, VT USA
,
S. Butenas
1   University of Vermont, Burlington, VT USA
,
A. Undas
2   Jagiellonian University, Krakow, Poland
,
K. Brummel-Ziedins
1   University of Vermont, Burlington, VT USA
› Author Affiliations
Further Information

Publication History

Publication Date:
08 January 2018 (online)

Also available at
    Permissions and Reprints

Summary

Our studies involve computational simulations, a reconstructed plasma/platelet proteome, whole blood in vitro and blood exuding from microvascular wounds. All studies indicate that in normal haemostasis, the binding of tissue factor (TF) with plasma factor (F) VIIa (extrinsic FXase complex) results in the initiation phase of the procoagulant response. This phase is negatively regulated by tissue factor pathway inhibitor (TFPI) in combination with antithrombin (AT) and the protein C (PC) pathway. The synergy between these inhibitors provides a threshold-limited reaction in which a stimulus of sufficient magnitude must be provided for continuation of the reaction. With sufficient stimulus, the FXa produced activates some prothrombin. This initial thrombin activates the procofactors and platelets required for presentation of the intrinsic FXase (FVIIIa- FIXa) and prothrombinase (FVa-FXa) complexes which drive the subsequent propagation phase; continuous downregulation of which is provided by AT and the thrombinthrombomodulin- PC complex. FXa generation during the propagation phase is largely (>90%) provided by the intrinsic FXase complex. TF is required for the initiation phase of the reaction but becomes non-essential once the propagation phase has been achieved. The propagation phase catalysts (FVIIIa-FIXa and FVa-FXa) continue to drive the reaction as blood is resupplied to the wound site by flow. Ultimately, the control of the reaction is governed by the pro- and anticoagulant dynamics and the supply of blood reactants to the site of a perforating injury. Our systems have been utilized to examine the qualities of hypothetical and novel antihaemorrhagic and anticoagulation agents and in epidemiologic studies of venous and arterial thrombosis and haemorrhagic pathology.

Keywords

Thrombin - blood coagulation - haemostasis - numerical models - phenotype variability
 

  • References

  • 1 Hockin MF, Jones KC, Everse SJ, Mann KG. A model for the stoichiometric regulation of blood coagulation. J Biol Chem 2002; 277: 18322-18333.
    CrossrefPubMedGoogle Scholar
  • 2 Lawson JH, Kalafatis M, Stram S, Mann KG. A model for the tissue factor pathway to thrombin. I. An empirical study. J Biol Chem 1994; 269: 23357-23366.
    PubMedGoogle Scholar
  • 3 Van’t Veer C, Mann KG. Regulation of tissue factor initiated thrombin generation by the stoichiometric inhibitors tissue factor pathway inhibitor, antithrombin- III, and heparin cofactor-II. J Biol Chem 1997; 272: 4367-4377.
    CrossrefPubMedGoogle Scholar
  • 4 Butenas S, van’t Veer C, Mann KG. Evaluation of the initiation phase of blood coagulation using ultrasensitive assays for serine proteases. J Biol Chem 1997; 272: 21527-21533.
    CrossrefPubMedGoogle Scholar
  • 5 Jones KC, Mann KG. A model for the tissue factor pathway to thrombin. II. A mathematical simulation. J Biol Chem 1994; 269: 23367-23373.
    PubMedGoogle Scholar
  • 6 Rand MD, Lock JB, van’t Veer C. et al. Blood clotting in minimally altered whole blood. Blood 1996; 88: 3432-3445.
    PubMedGoogle Scholar
  • 7 Brummel KE, Paradis SG, Butenas S, Mann KG. Thrombin functions during tissue factor-induced blood coagulation. Blood 2002; 100: 148-152.
    CrossrefPubMedGoogle Scholar
  • 8 Cawthern KM, van’t Veer C, Lock JB. et al. Blood coagulation in hemophilia A and hemophilia C. Blood 1998; 91: 4581-4592.
    PubMedGoogle Scholar
  • 9 Butenas S, Cawthern KM, van’t Veer C. et al. Antiplatelet agents in tissue factor-induced blood coagulation. Blood 2001; 97: 2314-2322.
    CrossrefPubMedGoogle Scholar
  • 10 Brummel-Ziedins K, Rivard GE, Pouliot RL. et al. Factor VIIa replacement therapy in factor VII deficiency. J Thromb Haemost 2004; 2: 1735-1744.
    CrossrefPubMedGoogle Scholar
  • 11 Undas A, Brummel KE, Musial J. et al. Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation. Circulation 2001; 103: 2248-2253.
    CrossrefPubMedGoogle Scholar
  • 12 Undas A, Brummel K, Musial J. et al. Blood coagulation at the site of microvascular injury: effects of low- dose aspirin. Blood 2001; 98: 2423-2431.
    CrossrefPubMedGoogle Scholar
  • 13 Undas A, Brzezinska-Kolarz B, Brummel-Ziedins K. et al. Factor XIII Val34Leu polymorphism and gamma-chain cross-linking at the site of microvascular injury in healthy and coumadintreated subjects. J Thromb Haemost 2005; 3: 2015-2021.
    CrossrefPubMedGoogle Scholar
  • 14 Undas A, Szuldrzynski K, Brummel-Ziedins KE. et al. Systemic blood coagulation activation in acute coronary syndromes. Blood. 2008 [Epub ahead of print].
    PubMedGoogle Scholar
  • 15 Mann KG, Nesheim ME, Church WR. et al. Surface- dependent reactions of the vitamin K-dependent enzyme complexes. Blood 1990; 76: 1-16.
    PubMedGoogle Scholar
  • 16 Jesty J, Silverberg SA. Kinetics of the tissue factor- dependent activation of coagulation Factors IX and X in a bovine plasma system. J Biol Chem 1979; 254: 12337-12345.
    PubMedGoogle Scholar
  • 17 Osterud B, Rapaport SI. Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation. Proc Natl Acad Sci USA 1977; 74: 5260-5264.
    CrossrefPubMedGoogle Scholar
  • 18 Lu G, Broze Jr GJ, Krishnaswamy S. Formation of factors IXa and Xa by the extrinsic pathway: differential regulation by tissue factor pathway inhibitor and antithrombin III. J Biol Chem 2004; 279: 17241-17249.
    CrossrefPubMedGoogle Scholar
  • 19 Orfeo T, Brufatto N, Nesheim ME. et al. The factor V activation paradox. J Biol Chem 2004; 279: 19580-19591.
    CrossrefPubMedGoogle Scholar
  • 20 Nesheim ME, Taswell JB, Mann KG. The contribution of bovine factor V and factor Va to the activity of prothrombinase. J Biol Chem 1979; 254: 10952-10962.
    PubMedGoogle Scholar
  • 21 Van Dieijen G, Tans G, Rosing J, Hemker HC. The role of phospholipid and factor VIIIa in the activation of bovine factor X. J Biol Chem 1981; 256: 3433-3442.
    PubMedGoogle Scholar
  • 22 Komiyama Y, Pedersen AH, Kisiel W. Proteolytic activation of human factors IX and X by recombinant human factor VIIa: effects of calcium, phospholipids, and tissue factor. Biochemistry 1990; 29: 9418-9425.
    CrossrefPubMedGoogle Scholar
  • 23 Van’t Veer C, Golden NJ, Mann KG. Inhibition of thrombin generation by the zymogen factor VII: implications for the treatment of hemophilia A by factor VIIa. Blood 2000; 95: 1330-1335.
    PubMedGoogle Scholar
  • 24 Orfeo T, Brummel-Ziedins KE, Gissel M. et al. The nature of the stable blood clot procoagulant activities. J Biol Chem 2008; 283: 9776-9786.
    CrossrefPubMedGoogle Scholar
  • 25 Brummel-Ziedins K, Orfeo T, Jenny NS. et al. Blood coagulation and fibrinolysis. In: Greer JP, Foerster J, Lukens J. et al (eds). Wintrobe’s Clinical Hematology. Philidelphia: Lippencott Williams & Wilkins; 2003: 677-774.
    Google Scholar
  • 26 Undas A, Sydor WJ, Brummel K. et al. Aspirin alters the cardioprotective effects of the factor XIII Val34Leu polymorphism. Circulation 2003; 107: 17-20.
    CrossrefPubMedGoogle Scholar
  • 27 Undas A, Brummel K, Musial J. et al. Pl(A2) polymorphism of beta(3) integrins is associated with enhanced thrombin generation and impaired antithrombotic action of aspirin at the site of microvascular injury. Circulation 2001; 104: 2666-2672.
    CrossrefPubMedGoogle Scholar
  • 28 Butenas S, van’t Veer C, Mann KG. “Normal“ thrombin generation. Blood 1999; 94: 2169-2178.
    PubMedGoogle Scholar
  • 29 Mann KG, Brummel-Ziedins K, Undas A, Butenas S. Does the genotype predict the phenotype? Evaluations of the hemostatic proteome. J Thromb Haemost 2004; 2: 1727-1734.
    CrossrefPubMedGoogle Scholar
  • 30 Brummel-Ziedins K, Vossen CY, Rosendaal FR. et al. The plasma hemostatic proteome: thrombin generation in healthy individuals. J Thromb Haemost 2005; 3: 1472-1481.
    CrossrefPubMedGoogle Scholar
  • 31 Brummel-Ziedins KE, Vossen CY, Butenas S. et al. Thrombin generation profiles in deep venous thrombosis. J Thromb Haemost 2005; 3: 2497-2505.
    CrossrefPubMedGoogle Scholar
  • 32 Brummel-Ziedins K, Undas A, Orfeo T. et al. Thrombin generation in acute coronary syndrome and stable coronary artery disease: dependence on plasma factor composition. J Thromb Haemost 2008; 6: 104-110.
    PubMedGoogle Scholar
  • 33 Mann KG, Brummel-Ziedins K, Orfeo T, Butenas S. Models of blood coagulation. Blood Cells Mol Dis 2006; 36: 108-117.
    CrossrefPubMedGoogle Scholar